Pfizer, Summit Therapeutics
3h
Summit Therapeutics Inc (SMMT) reports a robust cash reserve and debt-free status, while advancing key clinical trials and ...
Pfizer has teamed up with Summit Therapeutics to assess whether one of the industry’s hottest cancer candidates works well ...
Key Takeaways Summit Therapeutics shares dropped 14% Monday as it reported a fourth-quarter adjusted loss nearly double that ...
Robert Duggan; Executive Chairman of the Board, Co-Chief Executive Officer; Summit Therapeutics Inc Mahkam Zanganeh; President, Co-Chief Executive Officer, Director; Summit Therapeutics Inc Manmeet ...
Summit Therapeutics established a clinical trial collaboration with Pfizer to develop ivonescimab for NSCLC and solid tumors.
The partners will test Summit’s ivonescimab alongside Pfizer’s antibody-drug conjugates in hopes of finding “potentially ...
Summit Therapeutics shares fell after the company reported a wider loss in the fourth quarter. Shares were trading 14% lower at $19.11. The biopharmaceutical oncology company reported a loss of $61.2 ...
Pfizer partners with Summit Therapeutics to advance cancer treatments using ADCs and ivonescimab. Click here to find out why ...
Aggregate cash and cash equivalents and short-term investments were $412.3M and $186.2M at December 31, 2024 and December 31, 2023, ...
Akeso Inc. has announced that Summit Therapeutics Inc. (SMMT), its partner for ivonescimab, has entered into a clinical trial ...
CIBC Asset Management Inc lifted its holdings in Summit Therapeutics Inc. (NASDAQ:SMMT – Free Report) by 5.5% during the fourth quarter, HoldingsChannel.com reports. The firm owned 21,577 shares of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback